A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease - Richard, I H; McDermott, M P; Kurlan, R; Lyness, J M; Como, P G; Pearson, N; Factor, S A; Juncos, J; Serrano Ramos, C; Brodsky, M; Manning, C; Marsh, L; et al. (Neurology, 2012)
Keywords: Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - adverse effects; Adrenergic Uptake Inhibitors - therapeutic use; Adult; Antidepressive Agents - administration & dosage; Antidepressive Agents - adverse effects; Antidepressive Agents - therapeutic use; Cyclohexanols - administration & dosage; Cyclohexanols - therapeutic use; Delayed-Action Preparations - adverse effects; Delayed-Action Preparations - therapeutic use; Depressive Disorder - complications; Depressive Disorder - diagnosis; Depressive Disorder - drug therapy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Parkinson Disease - complications; Parkinson Disease - drug therapy; Paroxetine - administration & dosage; Paroxetine - adverse effects; Paroxetine - therapeutic use; Psychiatric Status Rating Scales - statistics & numerical data; Serotonin Uptake Inhibitors - administration & dosage; Serotonin Uptake Inhibitors - adverse effects; Serotonin Uptake Inhibitors - therapeutic use; Severity of Illness Index; Venlafaxine Hydrochloride